24 School Street
2nd Floor
Boston, MA 02108
United States
401 426 4664
https://www.allarity.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 5
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Thomas H. Jensen | Founder, CEO, Senior VP of Investor Relations & Director | N/A | N/A | 1978 |
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. | Co-Founder | 546,08k | N/A | 1955 |
Dr. Steen Meier Knudsen Ph.D. | Founder & Chief Scientific Officer | 185,11k | N/A | 1961 |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
El ISS Governance QualityScore de Allarity Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.